UK Edition
AdvertiseSubmit Company
Pharma JournalEvidence-Based Pharmaceutical Intelligence
CLINICAL RESEARCH

Flatiron Health

F

Flatiron Health

Clinical ResearchNew York City, United States
Visit Website

About Flatiron Health

Founded in 2012 and acquired by Roche in 2018, Flatiron Health has become the leading oncology-specific technology and real-world evidence company in the United States, connecting cancer care and research through a purpose-built data infrastructure. Its work centres on the premise that the information generated during routine cancer treatment holds untapped research value when structured and analysed correctly.

The company operates the OncoEMR electronic health record platform, used by community oncology practices across the country, alongside the broader oncology network that aggregates de-identified real-world data from millions of cancer patients. This dataset supports regulatory submissions, label expansions, health technology assessments, and clinical trial optimisation for pharmaceutical and biotechnology companies worldwide.

Flatiron's research services division works directly with life sciences sponsors and regulators, including the US Food and Drug Administration, to explore how real-world evidence can supplement or accelerate traditional clinical development pathways. The company is headquartered in New York City and operates as a subsidiary of the Roche Group, giving it access to global oncology expertise while maintaining a focused mandate on cancer data science.

Its therapy coverage spans solid tumours and haematological malignancies, with data assets covering breast cancer, lung cancer, colorectal cancer, leukaemia, lymphoma, and many additional indications. Researchers and commercial teams use Flatiron's curated datasets to understand treatment patterns, patient outcomes, and population-level trends in ways that prospective trials alone cannot capture.

Further information is available at flatiron.com.

Similar Companies

More in Clinical Research

A

Alcyomics

Founded in 2007 as a spinout from Newcastle University, Alcyomics develops and delivers human in vitro assays that enable pharmaceutical, biotechnology, chemical, and cosmetic companies to detect adverse immune reactions early in the development process, reducing both risk and cost before clinical stages are reached. The company's scientific foundation was built by Professor Anne Dickinson, whose three decades of research into transplantation and graft-versus-host disease at Newcastle University produced skin-based assay methodologies that have demonstrated over 80% correlation with clinical outcomes. That research led directly to Alcyomics' flagship technology: the patented Skimune platform, a highly sensitive human in vitro skin assay that uses matched skin and blood from the same donor to predict immune responses to small and large molecule drugs, monoclonal antibodies, cellular therapies, and cosmetic compounds. Building on the core Skimune test, Alcyomics has expanded its model portfolio to include Skimune 3D, a high-throughput full-thickness skin equivalent developed in collaboration with REPROCELL, as well as an innervated skin model for neurotoxicity assessment and a bioprinted osteo-arthritic joint model aimed at transforming drug discovery for osteoarthritis. The company operates from state-of-the-art laboratories within The Biosphere in Newcastle upon Tyne, serving a global client base that includes top-tier pharmaceutical organisations. Further information is available at alcyomics.com.

View profile
F

Fortrea

Spun out of Labcorp in 2023, Fortrea entered the contract research organisation market as an independent company with decades of accumulated trial execution expertise behind it. Headquartered in Durham, North Carolina, the organisation operates across more than 90 countries and employs tens of thousands of staff, making it one of the larger CROs active globally from the moment of its launch. Fortrea's core offering centres on clinical development services, spanning Phase I through Phase IV trials across a broad range of therapeutic categories. The company provides site management, patient recruitment, data management, bioanalytical laboratory services, and regulatory affairs support, giving sponsors a largely integrated pathway from early-phase work through post-market studies. Alongside its clinical operations, Fortrea runs an enabling services division that handles functional service provider arrangements, allowing biopharmaceutical clients to access specific capabilities without committing to a full-service model. This flexibility is particularly valued by mid-size and emerging biotechnology sponsors managing constrained timelines and budgets. The company is publicly listed on the Nasdaq stock exchange under the ticker FTRE. Its client base spans large multinational pharmaceutical companies, specialist biotechnology firms, and medical device developers, with therapeutic depth in oncology, central nervous system disorders, infectious disease, cardiovascular medicine, and immunology. Further information is available at fortrea.com.

View profile
A

ARC Regulatory

Diagnostic compliance sits at the core of what ARC Regulatory does. Operating as a specialist CRO and regulatory consultancy, the company supports pharmaceutical, diagnostics and laboratory clients navigating the intersection of IVD development, companion diagnostics and clinical research. Headquartered in the United Kingdom, ARC Regulatory positions itself explicitly as a partner for Dx compliance in translational research. The company's service model spans four interconnected pillars. Its regulatory team guides clients through the global regulatory landscape for IVD and CDx development, covering strategy, submissions and ongoing compliance. Clinical services provide IVD and CDx-focused monitoring with a global reach, supporting clinical performance studies from initiation through study close-out. A quality practice delivers QMS auditing, risk management and QMS implementation, while ARC Research Laboratories offers IVD development and validation services using advanced technologies. CRO and Sponsor Delegation for IVD Studies As a full-service CRO, ARC Regulatory guides sponsors through every phase of IVD and CDx clinical development. The company also offers IVD Clinical Study Sponsor Delegation, enabling clients to outsource the initiation and management of IVD studies to ARC's team. This model is particularly relevant to pharma sponsors supporting translational biomarkers in early clinical development, where the company provides proprietary risk-based monitoring of central testing laboratories across the full development life cycle. For diagnostics companies, ARC Regulatory supplies R&D compliance support and full-service CRO capabilities for clinical performance studies, meeting pharmaceutical sponsor expectations. Laboratory clients benefit from analytical testing capabilities, rounding out a broad but IVD-specific service offering. Further information is available at arc-regulatory.co.uk.

View profile
AdvertisementTeksyte LTD

List Your Company

Showcase your company to thousands of pharma professionals.

Submit Listing

Advertise With Us

Reach decision-makers in the pharmaceutical industry.

Learn More

We use cookies and analytics to understand how the site is used and to keep the service free. Choose Accept All to allow this, or Essential Only to use just the cookies we need to keep the site working. You can change your choice any time in our Cookie Policy